DDInter1838 DDInter875
Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Tositumomab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Tositumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Tositumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Tositumomab {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Tositumomab {u} may lead to a major life threatening interaction when taken with {v} Bivalirudin
Tositumomab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Ketorolac
Tositumomab may cause a minor interaction that can limit clinical effects when taken with Capsicum
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Tositumomab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Tositumomab may lead to a major life threatening interaction when taken with Bivalirudin
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Tositumomab may lead to a major life threatening interaction when taken with Ketorolac